Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7104114 | 0.84 | CA12 (0.40) | CA12CA1CA2CA9NR1I2 | |
| SCHEMBL428747 | 0.82 | PPARD (0.35) | CA12CA1CA2CA9TSHR | |
| SCHEMBL20211819 | 0.81 | CA12 (0.42) | CA12CA1CA2CA9NR1I2 | |
| SCHEMBL13987082 | 0.81 | CA12 (0.38) | CA12CA1CA2CA9NR1I2 | |
| SCHEMBL25760245 | 0.81 | CA12 (0.38) | CA12CA1CA2CA9NR1I2 | |
| SCHEMBL3229087 | 0.81 | CA12 (0.38) | CA12CA1CA2CA9TSHR | |
| SCHEMBL17772 | 0.77 | — | — | |
| SCHEMBL26720245 | 0.77 | TSHR (0.40) | CA12CA1CA2CA9NR1I2 | |
| SCHEMBL17202935 | 0.77 | CA12 (0.35) | CA12CA1CA2CA9NR1I2 | |
| SCHEMBL17202911 | 0.74 | TSHR (0.40) | CA12CA1CA2CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138979-A1 | PROCESSES FOR PREPARING KRAS INHIBITORS | INCYTE CORP (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026090336-A1 | PROCESSES FOR PREPARING KRAS INHIBITORS | INCYTE CORPORATION (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250179004-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | disclosed |
| US-12202782-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-4444421-A2 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| EP-4247783-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MACROCYCLIC MCL1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| US-20220177409-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2022108984-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MACROCYCLIC MCL1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2006107753-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| EP-1701955-A1 | ARYLALKENYL AND ARYLALKYNYL SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2006-09-20 | — | — | EP | disclosed |
| WO-2006095205-A1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| EP-1696912-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M Innovative Properties Company (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2006065280-A2 | ISOXAZOLE, DIHYDROISOXAZOLE, AND OXADIAZOLE SUBSTITUTED IMIDAZO RING COMPOUNDS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060100229-A1 | Pyrazolopyridines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-11 | — | — | US | disclosed |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| WO-2006021805-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005079195-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005066170-A1 | ARYLALKENYL AND ARYLALKYNYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | DYRK1A, DYRK2, DYRK1B | CA12 4456/4885CA1 3329/4885CA2 2594/4885 |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | CA12 4860/4885CA1 4510/4885CA2 4755/4885 |
| US-20220177409-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | MCL1, BCL3, XIAP | CA12 4761/4885CA1 4664/4885CA2 4799/4885 |
| US-12202782-B2 | Processes and intermediates for preparing MCL1 inhibitors | MCL1, BCL3, XIAP | CA12 4761/4885CA1 4664/4885CA2 4799/4885 |
| US-20060100229-A1 | Pyrazolopyridines and analogs thereof | IL4, IL2, IL4I1 | CA12 4790/4885CA1 4441/4885CA2 4526/4885 |
| US-20260138979-A1 | PROCESSES FOR PREPARING KRAS INHIBITORS | KRAS, NRAS, HRAS | CA12 3883/4885CA1 2644/4885CA2 875/4885 |
| US-20250179004-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | MCL1, BCL3, XIAP | CA12 4761/4885CA1 4664/4885CA2 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.